secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2024-10-10T23:59:59+00:00
Accession:  0000950170-24-113960
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.02, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos terminates key license with Precigen, pivots to oral obesity program; cash runway into Q1 2025
--------------------------------------------------------------------------------

- Terminated Amended and Restated License Agreement with Precigen effective Oct 4, 2024; Sleeping Beauty patent expiry in 2026 cited.
- Continues prosecuting TCR IP targeting KRAS, TP53, EGFR mutations and hunTR discovery platform.
- Exploring strategic alternatives including acquisition, merger, reverse merger, or sale of assets.
- Progressing internally developed small molecule oral obesity program; CMDO engaged for API manufacturing.
- Cash runway extended into Q1 2025 via overhead reductions; in vitro testing planned Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000095017024113960/0000950170-24-113960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000095017024113960/tcrt-20241004.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-113960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer